噬菌体疗法增强补体介导的细菌溶解并促进急性肺部感染清除
该研究在小鼠急性多重耐药铜绿假单胞菌肺部感染模型中,使用新分离的强裂解性噬菌体MMI-Ps1单剂鼻内给药,可显著提高保护水平并延长生存时间,即使感染后12小时给药仍具保护作用。体外结果首次显示噬菌体与补体对血清抵抗铜绿假单胞菌株具有协同清除作用,提示完整补体系统在噬菌体治疗清除铜绿假单胞菌感染中具有重要性。
要点
- 噬菌体MMI-Ps1单剂鼻内给药对小鼠急性多重耐药铜绿假单胞菌肺部感染有保护作用。
- 感染后12小时给予噬菌体治疗仍具保护作用。
- 噬菌体治疗增强补体介导的血清抵抗铜绿假单胞菌溶解。
核心结论
- 噬菌体疗法可增强补体介导的细菌溶解,并促进急性肺部感染中多重耐药铜绿假单胞菌的清除。
研究设计与样本
- 小鼠急性铜绿假单胞菌肺部感染模型,使用新分离的强裂解性噬菌体MMI-Ps1进行体内治疗评价。
- 体外评价噬菌体与补体对血清抵抗铜绿假单胞菌株的协同消除作用。
主要发现
- 感染后立即单剂鼻内给予MMI-Ps1可提供显著保护水平并延长生存时间。
- 感染后12小时给予噬菌体治疗仍具保护作用。
- 体外结果首次显示噬菌体与补体对血清抵抗铜绿假单胞菌株具有协同消除作用。
临床怎么用
- 提示噬菌体治疗多重耐药铜绿假单胞菌急性肺部感染时需关注宿主补体系统完整性。
- 噬菌体治疗的时间窗可能较宽,感染后延迟给药仍可能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emergence of multidrug-resistant (MDR) bacterial infections is a major problem in clinical medicine. Development of new strategies such as phage therapy may be a novel approach for treatment of life-threatening infections caused by MDR bacteria. A newly isolated phage, MMI-Ps1, with strong lytic activity was used for treatment of acute lung infection with Pseudomonas aeruginosa in a mouse model. Intranasal administration of a single dose of MMI-Ps1 immediately after infection provided a significant level of protection and increased the survival duration. Moreover, treatment of infected mice with phage as late as 12 hours after infection was still protective. Our in vitro results are the first to show the synergistic elimination of serum-resistant Pseudomonas strains by phage and complement. Phage therapy increases the efficacy of complement-mediated lysis of serum-resistant P. aeruginosa strains, indicating the importance of an intact complement system in clearing Pseudomonas infection during phage therapy.
引用
- Abd El-Aziz AM, Elgaml A, Ali YM, et al. Bacteriophage Therapy Increases Complement-Mediated Lysis of Bacteria and Enhances Bacterial Clearance After Acute Lung Infection With Multidrug-Resistant Pseudomonas aeruginosa. J Infect Dis. 2019. PMID: 30476337. doi:10.1093/infdis/jiy678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。